Syndax Pharmaceuticals (SNDX) Net Cash Flow (2015 - 2026)

Syndax Pharmaceuticals' Net Cash Flow history runs 12 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 4385.56% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$23.2 million (down 158.95% YoY), while the FY2025 annual figure was -$19.3 million, up 86.36% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.0 million, down from $18.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $200.8 million in Q4 2023, with the low at -$180.8 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$2.7 million (2023), against an average of -$5.4 million.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow jumped 6641.99% in 2023, then tumbled 4385.56% in 2026.
• Syndax Pharmaceuticals' Net Cash Flow stood at $3.0 million in 2022, then surged by 6641.99% to $200.8 million in 2023, then tumbled by 89.51% to $21.1 million in 2024, then declined by 14.51% to $18.0 million in 2025, then tumbled by 122.42% to -$4.0 million in 2026.
• Business Quant data shows SNDX's Net Cash Flow at -$4.0 million in Q1 2026, $18.0 million in Q4 2025, and $8.2 million in Q3 2025.